Sarasin is featuring a 2% discount on investments into the onshore version of its HealthSar fund whi...
Sarasin is featuring a 2% discount on investments into the onshore version of its HealthSar fund which launched on 8 April.
The onshore fund is effectively a clone of its existing Luxembourg-based HealthSar Sicav, which launched on 2 November 2001. It has been created as a sub-fund under the Sarasin Funds Oeic umbrella.
With the discount, which is available until the end of May, the initial fee on the retail share class is 3% and the annual management charge 1.5%.
Upfront commission for intermediaries is 3% and renewal will be agreed on an individual basis. The fund is both Isable and Pepable, with a minimum investment of £1,000. The institutional share class will carry a management fee of 0.75% and has a minimum investment of £1m.
HealthSar invests in pharmaceuticals, medical technology and biotechnology on a global basis, in keeping with the company's global-themed approach to investing.
The fund, benchmarked against a composite index comprising elements from the MSCI World Pharmaceutical index, the MSCI World Healthcare and Equipment Services index and the MSCI Biotechnology index, is managed by Roland Armbruster, along with Irene Puttner.
The portfolio will hold between 40 and 70 stocks, of which the majority will have a market capitalisation of E500m or above.
Two global vehicles
'Further plug advice gap'
Must appoint separate CEOs and boards
Advisers do come out well
Will report to Mark Till